v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Cash flows from operating activities:      
Net income $ 219,837 $ 199,353  
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation, depletion and amortization 349,809 168,894  
Loss on debt extinguishment 3,494 0  
Gain on sale of assets (5,516) (1,302)  
Impairment 1 3,919  
Deferred income taxes 29,765 26,966  
Net loss on derivative instruments 20,281 27,577  
Net (gain) loss from investment in unconsolidated affiliate 4,900 (16,296)  
Equity-based compensation expenses 6,876 4,771  
Deferred financing costs amortization and other (9,763) 2,663  
Working capital and other changes:      
Change in accounts receivable, net (25,369) (62,081)  
Change in inventory (9,499) (9,471)  
Change in prepaid expenses 5,205 (291)  
Change in accounts payable, interest payable and accrued liabilities 60,353 29,147  
Change in other assets and liabilities, net 6,519 32,849  
Net cash provided by operating activities 656,893 406,698  
Cash flows from investing activities:      
Capital expenditures (308,913) (222,149)  
Acquisitions (17,876) (334)  
Proceeds from divestitures 6,204 2,371  
Derivative settlements 972 (12,062)  
Contingent consideration received 25,000 25,000  
Distributions from investment in unconsolidated affiliate 2,343 2,287  
Net cash used in investing activities (292,270) (204,887)  
Cash flows from financing activities:      
Proceeds from revolving credit facility 1,060,000 0  
Principal payments on revolving credit facility (1,445,000) 0  
Repayment and discharge of senior notes (401,432) 0  
Issuance of senior notes 750,000 0  
Deferred financing costs (12,999) 0  
Repurchases of common stock (215,153) (31,999)  
Tax withholding on vesting of equity-based awards (14,356) (46,051)  
Dividends paid (86,464) (152,389)  
Payments on finance lease liabilities (415) (386)  
Proceeds from warrants exercised 0 7,370  
Net cash used in financing activities (365,819) (223,455)  
Decrease in cash and cash equivalents (1,196) (21,644)  
Cash and cash equivalents:      
Beginning of period 36,950 317,998 $ 317,998
End of period 35,754 296,354 $ 36,950
Supplemental non-cash transactions:      
Change in accrued capital expenditures 46,208 25,312  
Change in asset retirement obligations 540 973  
Dividends payable $ 7,623 $ 17,587